Research Project

Project Title:

A randomized, multicenter, double-blind, parallel, active-control study of the effects of Sparsentan, a dual endothelin receptor and angiotensin receptor blocker, on renal outcomes in patients with primary focal segmental glomerulosclerosis

Project Type:

Clinical Trial, Enrolment ongoing

Disease group(s):

Immune glomerulopathies

Project Summary:

A randomized, multicenter, double-blind, parallel, active-control study of the effects of Sparsentan, a dual endothelin receptor and angiotensin receptor blocker, on renal outcomes in patients with primary focal segmental glomerulosclerosis

Lead principal investigator(s):

Olga Baraldi, Bologna

Co-investigator(s):

Valeria Aiello, Bologna
Simona Barbuto, Bologna

Project Period:

04/2020   -   12/2024

Sponsors:

Industry

« Back to research page